| Conclusion | rs12979860 genotype is a significant independent predictor of response to PEG-IFN/RBV in patients with chronic HCV infectio tests for this genotype might be used to determine the best course of treatment for patients considering antiviral therapy.;The expression of hepatic ISGs is strongly associated with treatment response and genetic variation of IL28B. The differential role of host and viral factors as predicting factors may also be present.;In patients with recurrent HCV infection after orthotopic liver transplantation, combination analyses of single nucleotide polymorphisms of IL28B in recipient and donor tissues and mutations in HCV RNA allow prediction of SVR to PEG-IFN/RBV therapy.;The good response IL28B variant was strongly associated with lower level ISG expression.;HCV sequences from these individuals revealed 29 significant associations between specific HLA types within the new hosts and variations within their viruses, which likely represent new viral adaptations.;IL28B polymorphisms and HCV core amino acid 70 substitutions contribute independently to an SVR to peg-interferon plus ribavirin combination therapy.;Recipient IL28B TT genotype is associated with more severe histological recurrence of HCV.Conclusion1 |
